Company
Problem statement
Food allergies affect over 120M people across the US and EU, with incidence still rising, especially in children. Current therapies are limited to symptom management (antihistamines, epinephrine) or burdensome allergen-specific immunotherapy. There is no short, broad-spectrum, causal treatment that addresses the root mechanism of IgE-mediated food allergies.
Solution
AE001 is a short oral therapy that reprograms the immune system by inducing regulatory T cells, reducing IgE levels and blocking allergic reactions. It works across multiple food allergens, requires only periodic dosing, and preserves overall immunity.
Value proposition
- First causal therapy for IgE-mediated food allergies, addressing root immune dysfunction.
- Broad-spectrum efficacy – works across multiple allergens simultaneously, unlike allergen-specific immunotherapies.
- Short treatment cycle – a few days of dosing, repeated only every few months.
- Selective mechanism – blocks allergic reactions without weakening overall immunity.
- Preventive potential – not only treats but may also prevent the onset of food allergies.
What's next
Project
Next steps
Confirmation of the molecule’s activity in in vitro and in vivo studies.
Development of a therapeutic mimic with proven activity.
Selection of three candidate molecules for further research / identification of the most active form of particle.